BRPI0410922A - processo para a formação de um composto, e, composto - Google Patents

processo para a formação de um composto, e, composto

Info

Publication number
BRPI0410922A
BRPI0410922A BRPI0410922-8A BRPI0410922A BRPI0410922A BR PI0410922 A BRPI0410922 A BR PI0410922A BR PI0410922 A BRPI0410922 A BR PI0410922A BR PI0410922 A BRPI0410922 A BR PI0410922A
Authority
BR
Brazil
Prior art keywords
compound
forming
useful
dihydroxyhept
hyperlipoproteinemia
Prior art date
Application number
BRPI0410922-8A
Other languages
English (en)
Inventor
Jeffrey Norman Crabb
John Horbury
Nigel Philip Taylor
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33512687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of BRPI0410922A publication Critical patent/BRPI0410922A/pt
Publication of BRPI0410922B1 publication Critical patent/BRPI0410922B1/pt
Publication of BRPI0410922B8 publication Critical patent/BRPI0410922B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PROCESSO PARA A FORMAçãO DE UM COMPOSTO, E, COMPOSTO". é descrito um processo melhorado para a manufatura de sal de cálcio de ácido (E)-7-¢4-(4-fluoro-fenil)-6-isopropil-2-¢(metil-(metil-sulfonil)-amino!-pirimi din-5-il!-(3R,5S)-3,5-di-hidróxi-hept-6-enóico, Fórmula (1), que é útil para a produção de um fármaco útil no tratamento de, inter alia, hipercolesterolemia, hiperlipoproteinemia e aterosclerose.
BRPI0410922A 2003-06-05 2004-06-03 processo para a formação de um composto BRPI0410922B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0312896.4A GB0312896D0 (en) 2003-06-05 2003-06-05 Chemical process
GBGB0324793.9A GB0324793D0 (en) 2003-06-05 2003-10-24 Chemical process
PCT/GB2004/002373 WO2004108691A1 (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt

Publications (3)

Publication Number Publication Date
BRPI0410922A true BRPI0410922A (pt) 2006-06-27
BRPI0410922B1 BRPI0410922B1 (pt) 2016-02-23
BRPI0410922B8 BRPI0410922B8 (pt) 2021-05-25

Family

ID=33512687

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410922A BRPI0410922B8 (pt) 2003-06-05 2004-06-03 processo para a formação de um composto

Country Status (26)

Country Link
US (1) US8063213B2 (pt)
EP (1) EP1633727B1 (pt)
JP (1) JP4651615B2 (pt)
KR (1) KR101099934B1 (pt)
CN (1) CN100422157C (pt)
AR (1) AR044773A1 (pt)
AT (1) ATE464297T1 (pt)
AU (1) AU2004245291B2 (pt)
BR (1) BRPI0410922B8 (pt)
CA (1) CA2527314C (pt)
CO (1) CO5640116A2 (pt)
DE (1) DE602004026576D1 (pt)
ES (1) ES2341858T3 (pt)
GB (2) GB0312896D0 (pt)
HK (1) HK1087405A1 (pt)
IL (1) IL172075A (pt)
IS (1) IS2751B (pt)
MX (1) MXPA05013128A (pt)
MY (1) MY140820A (pt)
NO (1) NO332971B1 (pt)
NZ (1) NZ543962A (pt)
RU (1) RU2361864C2 (pt)
SA (1) SA04250223B1 (pt)
TW (1) TWI341310B (pt)
UY (1) UY28341A1 (pt)
WO (1) WO2004108691A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
NZ531033A (en) * 2001-07-13 2005-07-29 Astrazeneca Uk Ltd Preparation of a 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound or analogous aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US7524955B2 (en) 2002-12-16 2009-04-28 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
KR100945763B1 (ko) * 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
JP5416403B2 (ja) 2005-06-24 2014-02-12 レツク・フアーマシユーテイカルズ・デー・デー 純粋な非結晶ロスバスタチンカルシウムの調製方法
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
EP1919880A2 (en) * 2005-08-16 2008-05-14 Teva Pharmaceutical Industries Ltd. Rosuvastatin calcium with a low salt by-product content
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en) 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
EP2309992B1 (en) 2008-06-27 2017-10-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
US20110245285A1 (en) * 2008-09-09 2011-10-06 Biocon Limited Process for preparation of rosuvastatin acetonide calcium
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US8536330B2 (en) 2010-04-23 2013-09-17 Ranbaxy Laboratories Limited Intermediates for the preparation of HMG-CoA reductase inhibitors
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
CN105753834B (zh) * 2016-03-25 2018-08-21 河南师范大学 一种瑞舒伐他汀钙关键手性中间体的合成方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
WO1990003973A1 (en) 1988-10-06 1990-04-19 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DE59307409D1 (de) 1992-07-02 1997-10-30 Hoechst Ag Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
EA000474B1 (ru) 1995-07-17 1999-08-26 Варнер-Ламберт Компани Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
DE69719755T2 (de) 1996-06-24 2003-11-20 Novartis Ag Polymorphe verbindungen
AU1683000A (en) 1998-12-10 2000-06-26 Kaneka Corporation Process for producing simvastatin
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP2206497A1 (en) 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CZ20031166A3 (cs) 2000-10-05 2004-04-14 Biogal Gyogyszergyar Rt Sodná sůl pravastatinu, která v podstatě neobsahuje pravastatin lakton a epi-pravastatin a kompozice na její bázi
IL155890A0 (en) 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (pt) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
TR200400600T3 (tr) 2001-06-06 2004-06-21 Bristol-Myers Squibb Company Kiral diol sülfonlar ve dihidroksi asit HMG COA redüktaz inhibitörlerinin hazırlanmsı için işlem
NZ531033A (en) 2001-07-13 2005-07-29 Astrazeneca Uk Ltd Preparation of a 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound or analogous aminopyrimidine compounds
CZ2004337A3 (cs) 2001-08-16 2005-01-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy vápenatých solí statinů
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050032875A1 (en) 2001-08-22 2005-02-10 Heinz Wolleb Process for the preparation of indole derivatives
US7407772B2 (en) 2001-09-24 2008-08-05 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AR039836A1 (es) 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
SI1578733T1 (sl) 2002-12-10 2011-07-29 Ranbaxy Lab Ltd Postopek za pridobitev rosuvastatina
US7524955B2 (en) 2002-12-16 2009-04-28 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
AU2003247327A1 (en) 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1678148A1 (en) 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
CA2550742A1 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7932387B2 (en) 2005-01-31 2011-04-26 Basf Se Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
TWI341310B (en) 2011-05-01
ATE464297T1 (de) 2010-04-15
KR20060017848A (ko) 2006-02-27
AU2004245291B2 (en) 2008-02-14
GB0324793D0 (en) 2003-11-26
US8063213B2 (en) 2011-11-22
HK1087405A1 (en) 2006-10-13
JP2006526602A (ja) 2006-11-24
JP4651615B2 (ja) 2011-03-16
MXPA05013128A (es) 2006-03-16
WO2004108691A1 (en) 2004-12-16
AR044773A1 (es) 2005-10-05
NO20055730L (no) 2005-12-27
SA04250223B1 (ar) 2008-12-23
GB0312896D0 (en) 2003-07-09
NO332971B1 (no) 2013-02-11
MY140820A (en) 2010-01-29
NZ543962A (en) 2008-09-26
CA2527314C (en) 2012-02-21
EP1633727A1 (en) 2006-03-15
CA2527314A1 (en) 2004-12-16
DE602004026576D1 (de) 2010-05-27
IS8217A (is) 2006-01-02
IS2751B (is) 2011-09-15
US20080221323A1 (en) 2008-09-11
CN100422157C (zh) 2008-10-01
BRPI0410922B1 (pt) 2016-02-23
EP1633727B1 (en) 2010-04-14
TW200510337A (en) 2005-03-16
UY28341A1 (es) 2005-01-31
RU2005138370A (ru) 2006-07-10
BRPI0410922B8 (pt) 2021-05-25
CO5640116A2 (es) 2006-05-31
IL172075A (en) 2011-06-30
KR101099934B1 (ko) 2011-12-28
RU2361864C2 (ru) 2009-07-20
NO20055730D0 (no) 2005-12-05
CN1798741A (zh) 2006-07-05
AU2004245291A1 (en) 2004-12-16
ES2341858T3 (es) 2010-06-29

Similar Documents

Publication Publication Date Title
BRPI0410922A (pt) processo para a formação de um composto, e, composto
BR0313394A (pt) Processo para a fabricação de sal de cálcio do ácido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfo nil)amino]pirimidin-5-il]-(3r,5s)-3,5 -diidroxiept-6-enóico, e, produto
IS2410B (is) Kristallað bis[(E)-7-[4-(4-flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó] Pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru]kalsíum salt
BRPI0415681A (pt) processo para a fabricação do sal de cálcio de ácido (e) -7-[4-(4-fluorofenil)-6-isopropil-2-[metil (metil sulfonil) amino] pirimidin-5-il] (3r, 5s) 3,5-dihidroxihept-6-enóico, composto, processo para formação de sal de cálcio de bis ([ácido (e)-7-[-4-(4-fluorofenil)-6-isopropil-2-[metil (metilsulfonil)amino] pirimidin-5-il](3r, 5s)-3,5-dihidroxihept-6-enóico], e, uso de um composto
HRP20090335T1 (en) CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT
ATE382610T1 (de) Cristallinsalze von 7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino pyrimidin-5-yl -(3r,5s)-3,5-dihydroxyhept-6- ensäure
EA200900493A1 (ru) Гидраты 2-хлор-5-[3,6-дигидро-3-метил-2,6-диоксо-4-(трифторметил)-1-(2н)-пиримидинил]-4-фтор-n-[[метил-(1-метилэтил)амино]сульфонил]бензамида
CL2007001807A1 (es) Composicion farmaceutica oral que comprende el acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-(metil-(metilsulfonil)-pirimidin-5-il]-(3r,5s)-3,5-dihodroxihept-6enoico, o una sal de ella y con una formulacion recubridora que contiene oxido ferrico; uso de la formulacion recubridora; util como inhibidor de hmg-coa reductasa.
EA200401533A1 (ru) Способ получения росувастатина
CL2010000284A1 (es) Procedimientos para la preparacion de 4-(2-cianoetenil)-2,6-dimetilanilina a partir de 2,6-dimetil-4-sustituida-anilina. (divisional de solicitud 2003-01598)
BR122012009534C8 (pt) 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto
DK1578733T3 (da) Fremgangsmåde til fremstilling af rosuvastatin
PE20061025A1 (es) Anilidas de acido pirazolcarboxilico
DK1897546T3 (da) Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre
BR0312593A (pt) Aciluréias substituìdas por uréia e uretano, processo para a sua produção e sua aplicação
DE60231912D1 (de) Trioxanderivate zur verwendung als antimalaria- oder antikrebs-verbindungen
UA89614C2 (ru) Способ получения кальциевой соли розовастатина
BR9909759A (pt) Processo para a fabricação de um composto

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)

Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO ART. 6O, II, "B" DA RESOLUCAO 191/08.

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)

Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO ART. 6O, II, "B" DA RESOLUCAO 191/08.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF